Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Income (2020 - 2025)

Apellis Pharmaceuticals has reported Net Income over the past 6 years, most recently at -$203.6 million for Q4 2025.

  • Quarterly results put Net Income at -$203.6 million for Q4 2025, down 1393.81% from a year ago — trailing twelve months through Dec 2025 was -$122.2 million (up 30.21% YoY), and the annual figure for FY2025 was -$122.2 million, up 30.22%.
  • Net Income for Q4 2025 was -$203.6 million at Apellis Pharmaceuticals, down from $215.7 million in the prior quarter.
  • Over the last five years, Net Income for APLS hit a ceiling of $402.7 million in Q4 2022 and a floor of -$219.2 million in Q2 2021.
  • Median Net Income over the past 5 years was -$107.1 million (2023), compared with a mean of -$61.2 million.
  • Peak annual rise in Net Income hit 475.46% in 2025, while the deepest fall reached 1393.81% in 2025.
  • Apellis Pharmaceuticals' Net Income stood at $283.4 million in 2021, then soared by 42.1% to $402.7 million in 2022, then crashed by 122.0% to -$88.6 million in 2023, then skyrocketed by 84.62% to -$13.6 million in 2024, then plummeted by 1393.81% to -$203.6 million in 2025.
  • The last three reported values for Net Income were -$203.6 million (Q4 2025), $215.7 million (Q3 2025), and -$42.2 million (Q2 2025) per Business Quant data.